HC Wainwright & Co. Reiterates Buy on Aridis Pharmaceuticals, Maintains $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino has reiterated a 'Buy' rating on Aridis Pharmaceuticals (OTC:ARDS) and maintained a $2 price target.
November 06, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aridis Pharmaceuticals has received a reiterated 'Buy' rating and a maintained $2 price target from HC Wainwright & Co.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Aridis Pharmaceuticals. This could potentially attract investors and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100